gallium ga-68 gozetotide · Novartis · NDA 215841
Locametz
Earliest generic entry, as listed
9 Mar 2036
Blocked by patent: US 12109277. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12109277 | use U-4002 | 9 Mar 2036 |
| US 11369590 | substance, product, use U-3400 | 15 Aug 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215841 · 001 · RLD | powder, intravenous | N/A | 9 Mar 2036 |